CD4+ T Cell Responses to Toxoplasma gondii Are a Double-Edged Sword. Academic Article uri icon

Overview

abstract

  • CD4+ T cells have been found to play critical roles in the control of both acute and chronic Toxoplasma infection. Previous studies identified a protective role for the Toxoplasma CD4+ T cell-eliciting peptide AS15 (AVEIHRPVPGTAPPS) in C57BL/6J mice. Herein, we found that immunizing mice with AS15 combined with GLA-SE, a TLR-4 agonist in emulsion adjuvant, can be either helpful in protecting male and female mice at early stages against Type I and Type II Toxoplasma parasites or harmful (lethal with intestinal, hepatic, and spleen pathology associated with a storm of IL6). Introducing the universal CD4+ T cell epitope PADRE abrogates the harmful phenotype of AS15. Our findings demonstrate quantitative and qualitative features of an effective Toxoplasma-specific CD4+ T cell response that should be considered in testing next-generation vaccines against toxoplasmosis. Our results also are cautionary that individual vaccine constituents can cause severe harm depending on the company they keep.

publication date

  • September 14, 2023

Identity

PubMed Central ID

  • PMC10535856

Scopus Document Identifier

  • 85172172276

Digital Object Identifier (DOI)

  • 10.3390/vaccines11091485

PubMed ID

  • 37766162

Additional Document Info

volume

  • 11

issue

  • 9